Parkinson’s disease, a relentless neurodegenerative disorder, impacts the lives of over one million individuals in the United States and a staggering ten million globally, presenting a complex constellation of symptoms that erode quality of life. This progressive condition manifests through debilitating tremors, profound motor control difficulties, disruptive sleep disturbances, and a gradual cognitive decline. While current therapeutic interventions, ranging from long-term pharmaceutical regimens to more invasive procedures like deep brain stimulation (DBS), offer some mitigation of symptoms, they fall short of halting the disease’s inexorable march or providing a definitive cure.
A landmark collaborative effort, spearheaded by researchers at China’s Changping Laboratory in conjunction with Washington University School of Medicine in St. Louis and an array of international partners, has pinpointed a specific neural architecture demonstrably linked to the core pathological features of Parkinson’s disease. Their investigation has illuminated the critical role played by a brain network designated as the somato-cognitive action network, or SCAN, in the manifestation of this disorder. Employing a non-invasive experimental technique known as transcranial magnetic stimulation (TMS), the research team observed a remarkable therapeutic effect: patients subjected to targeted stimulation of the SCAN experienced more than double the degree of symptom alleviation compared to those whose stimulation was directed at adjacent brain regions.
These groundbreaking findings, formally published on February 4th in the esteemed scientific journal Nature, represent a significant paradigm shift, challenging long-held assumptions about the underlying mechanisms of Parkinson’s disease and heralding a new era of highly precise and personalized treatment strategies.
"This extensive body of work unequivocally demonstrates that Parkinson’s disease can be characterized as a disorder of the SCAN, and our data provide compelling evidence that by precisely targeting this network in a personalized manner, we can achieve superior treatment outcomes than were previously attainable," stated co-author Nico U. Dosenbach, MD, PhD, a distinguished neurologist and the David M. & Tracy S. Holtzman Professor of Neurology at WashU Medicine. "The potential exists not merely to alleviate symptoms but to actively modulate activity within the SCAN, thereby potentially slowing or even reversing the pathological progression of the disease itself."
Deconstructing the SCAN: A Nexus of Movement and Cognition
The SCAN was initially described by Dosenbach in a seminal publication in Nature in 2023, delineating its location within the motor cortex, the brain’s principal command center for orchestrating voluntary body movements. This network’s fundamental function involves the intricate translation of intended actions into executable physical commands and the subsequent continuous monitoring of the execution and outcome of those actions. Given that Parkinson’s disease extends its influence far beyond motor impairments, affecting vital physiological processes such as digestion, sleep regulation, motivational drives, and complex cognitive functions, senior author Hesheng Liu, PhD, joined forces with Dosenbach to explore whether dysregulation within the SCAN could account for this broad spectrum of clinical manifestations and concurrently serve as a viable therapeutic target.
To rigorously test this hypothesis, Liu’s research group embarked on a comprehensive analysis of neuroimaging data derived from a substantial cohort of over 800 participants, drawn from multiple research institutions across both the United States and China. This diverse study population included individuals diagnosed with Parkinson’s disease who were undergoing various therapeutic interventions, such as DBS, non-invasive therapies like transcranial magnetic stimulation and focused ultrasound, and pharmacological treatments. For comparative purposes, the study also incorporated data from healthy volunteers and individuals diagnosed with other movement disorders.
Unveiling Aberrant Neural Connectivity
The in-depth analysis revealed a consistent pattern in Parkinson’s disease: an excessive degree of connectivity between the SCAN and the subcortex, a collection of brain structures critically involved in regulating emotions, consolidating memories, and executing motor commands. Crucially, the research demonstrated that the efficacy of all four therapeutic modalities examined within the study was maximized when they effectively reduced this heightened inter-network connectivity. The restoration of a more balanced functional relationship between these interconnected regions appeared to normalize the activity within the neural circuits responsible for the planning and coordination of complex actions.
"For many decades, the understanding of Parkinson’s disease has been predominantly centered on motor deficits and the dysfunction of the basal ganglia, the brain region primarily responsible for controlling muscle movements," explained Liu. "Our research fundamentally reframes this perspective, indicating that the disease originates from a much more extensive network-level dysfunction. The SCAN exhibits hyperconnectivity with key subcortical regions implicated in Parkinson’s disease, and this aberrant neural wiring disrupts not only motor function but also interconnected cognitive and visceral processes."
Precision Neuromodulation: A Promising Therapeutic Frontier
Building upon these profound insights, the research team engineered a sophisticated precision therapeutic system specifically designed to target the SCAN without the necessity of surgical intervention, achieving an unprecedented level of accuracy down to the millimeter. This innovative approach leverages transcranial magnetic stimulation (TMS), a technique that delivers precisely calibrated magnetic pulses to specific brain regions via a device positioned on the scalp. In a carefully controlled clinical trial involving 18 patients who received SCAN-targeted stimulation, a remarkable 56% demonstrated significant symptom improvement after a two-week treatment period. In stark contrast, only 22% of 18 patients who received stimulation directed at nearby brain areas exhibited improvement, underscoring a more than 2.5-fold increase in therapeutic effectiveness for the SCAN-targeted approach.
"The advantage of non-invasive treatments like this is that we can initiate neuromodulation therapies much earlier in the disease course than is currently feasible with DBS," Dosenbach elaborated, emphasizing the significant benefit of avoiding brain surgery. "This opens up possibilities for earlier intervention and potentially a more proactive management of the disease."
Further foundational research is still imperative to fully elucidate the intricate contributions of different components within the SCAN to the diverse array of Parkinson’s symptoms, he noted.
Looking towards the future, Dosenbach is spearheading the launch of additional clinical trials in collaboration with Turing Medical, a startup company he co-founded within WashU Medicine. These forthcoming studies are slated to evaluate a novel non-invasive therapy employing surface electrode arrays strategically placed over SCAN regions to address gait disturbances commonly experienced by individuals with Parkinson’s disease. Furthermore, he intends to investigate the potential of low-intensity focused ultrasound as another non-invasive modality for modulating SCAN activity through precisely targeted acoustic energy.
This pioneering research was made possible through substantial support from the Changping Laboratory, the U.S. National Institutes of Health (grants MH096773, MH122066, MH121276, MH124567, NS129521, NS088590, R01NS131405, U01NS098969, and U01NS117836), the National Natural Science Foundation of China (grants 81527901, 81720108021, 81971689, 31970979, and 82090034), the National Key R&D Program of China (grant 2017YFE0103600), the Intellectual and Developmental Disabilities Research Center, the Kiwanis Foundation, the Washington University Hope Center for Neurological Disorders, and the Collaborative Innovation Center of Neuropsychiatric Disorders and Mental Health of Anhui Province (grant 2020xkjT05). The content presented herein is solely the responsibility of the authors and does not necessarily reflect the official viewpoints of the National Institutes of Health.
H.L. holds the position of chief scientist at Neural Galaxy Inc. L.L. serves on the scientific advisory board for Beijing Pins Medical Co., Ltd and is recognized as an inventor on issued patents and patent applications pertaining to the deep brain stimulator utilized in this research. N.U.F.D. has a financial interest in Turing Medical Inc. and may derive financial benefit from the company’s success in marketing FIRMM motion monitoring software, BullsAI neuromodulation targeting software, or PACE neuromodulation systems. E.M.G. and N.U.F.D. may receive royalty income stemming from FIRMM technology developed at Washington University School of Medicine and subsequently licensed to Turing Medical Inc. N.U.F.D. is a co-founder of Turing Medical Inc. These potential conflicts of interest have undergone thorough review and are actively managed by Washington University School of Medicine. S.L. provides consulting services to Iota Biosciences. P.A.S. receives fellowship education support from Medtronic and Boston Scientific.
About the Author
